Haemonetics Corporation $HAE Shares Acquired by Barrow Hanley Mewhinney & Strauss LLC

Barrow Hanley Mewhinney & Strauss LLC grew its position in Haemonetics Corporation (NYSE:HAE) by 16.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 559,972 shares of the medical instruments supplier’s stock after purchasing an additional 79,138 shares during the period. Barrow Hanley Mewhinney & Strauss LLC owned approximately 1.20% of Haemonetics worth $27,293,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. EverSource Wealth Advisors LLC increased its position in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares during the period. Versant Capital Management Inc increased its holdings in shares of Haemonetics by 216.4% during the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 567 shares during the period. Byrne Asset Management LLC bought a new stake in shares of Haemonetics during the third quarter valued at about $42,000. Hantz Financial Services Inc. lifted its holdings in Haemonetics by 792.1% in the third quarter. Hantz Financial Services Inc. now owns 1,124 shares of the medical instruments supplier’s stock worth $55,000 after purchasing an additional 998 shares during the period. Finally, Elevation Point Wealth Partners LLC bought a new position in Haemonetics in the 2nd quarter valued at about $64,000. Institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Needham & Company LLC cut Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th. BTIG Research restated a “buy” rating and issued a $88.00 price objective on shares of Haemonetics in a report on Friday, February 6th. Citigroup lowered their target price on Haemonetics from $75.00 to $70.00 and set a “neutral” rating on the stock in a report on Wednesday. Raymond James Financial restated an “outperform” rating and set a $90.00 price objective on shares of Haemonetics in a research report on Friday, November 14th. Finally, Barrington Research set a $94.00 price objective on shares of Haemonetics in a research note on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $83.89.

Haemonetics Stock Down 3.4%

Shares of Haemonetics stock opened at $60.69 on Thursday. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32. The company has a market cap of $2.82 billion, a P/E ratio of 16.72, a P/E/G ratio of 1.31 and a beta of 0.28. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01. The stock has a 50-day moving average price of $67.49 and a 200 day moving average price of $64.66.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, topping the consensus estimate of $1.27 by $0.04. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business had revenue of $338.97 million during the quarter, compared to analysts’ expectations of $331.90 million. During the same period last year, the company posted $1.19 earnings per share. The firm’s quarterly revenue was down 2.7% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, analysts expect that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.